Micardis
Brand names,
Micardis
Analogs
Micardis
Brand Names Mixture
Micardis
Chemical_Formula
C7H9ClO6P2S
Micardis
RX_link
http://www.rxlist.com/cgi/generic2/tiludronate.htm
Micardis
fda sheet
Micardis
msds (material safety sheet)
Micardis
Synthesis Reference
No information avaliable
Micardis
Molecular Weight
318.609 g/mol
Micardis
Melting Point
No information avaliable
Micardis
H2O Solubility
No information avaliable
Micardis
State
Solid
Micardis
LogP
0.549
Micardis
Dosage Forms
Tablets for oral administration containing 240 mg tiludronate disodium
Micardis
Indication
For treatment of Paget's disease of bone (osteitis deformans).
Micardis
Pharmacology
Tiludronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and clodronate. Tiludronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the tiludronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface.
Micardis
Absorption
The mean oral bioavailability in healthy male subjects is 6% after an oral dose equivalent to 400 mg tiludronic acid administered after an overnight fast and 4 hours before a standard breakfast. In single-dose studies, bioavailability was reduced by 90% when an oral dose equivalent to 400 mg tiludronic acid was administered with, or 2 hours after, a standard breakfast compared to the same dose administered after an overnight fast and 4 hours before a standard breakfast.
Micardis
side effects and Toxicity
Based on the known action of tiludronate, hypocalcemia is a potential consequence of overdose. In one patient with hypercalcemia of malignancy, intravenous administration of high doses (800 mg/day total dose, 6 mg/kg/day for 2 days) was associated with acute renal failure and death.
Micardis
Patient Information
Micardis
Organisms Affected
Humans and other mammals